

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce the updates on product development of the Group as follows:

1. The Group, being the first of the PRC entities, has obtained the approval for drug production and registration for Fat-soluble Vitamin Injection (I) (10ml) from National Medical Products Administration of China (the “NMPA”), being under type 3 chemical drug and regarded as passing the consistency evaluation. This product is mainly used for meeting the daily needs of children under 11 years old and infants for fat-soluble vitamin A, vitamin D₂, vitamin E and vitamin K₁ as nutritional supplement through intravenous infusion.
2. The Group has obtained the approvals for drug production and registration for Metformin Hydrochloride Tablets (0.5g and 0.25g) from the NMPA, being under type 4 and regarded as passing the consistency evaluation. This product is mainly used for treatment of type 2 diabetes where diet and exercise alone are ineffective in controlling blood sugar.
3. The Group has obtained the approval for drug production and registration for Doxazosin Mesylate Extended Release Tablets (4mg) from the NMPA, being under type 4 and regarded as passing the consistency evaluation. This product is mainly used for symptomatic treatment of benign prostatic hyperplasia and for treatment of hypertension. As stated in the Company’s announcement dated 8 April 2024, the Group’s Doxazosin Mesylate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 6 May 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.